mRNA vaccines are too slow, dog owners have lost their beloved dogs, and the world's first AI-customized dog cancer vaccine has arrived.

Remember the "real-life 'Drug God'" story that went viral across all platforms a few months ago?

An Australian AI guru with no professional medical background, in order to save his beloved dog suffering from advanced cancer, taught himself genomics, and with the help of ChatGPT and AlphaFold, independently developed the world's first custom mRNA cancer vaccine.

After one injection, the tennis-ball-sized tumor on the dog's leg miraculously shrank by 75%, and the dog successfully extended its lifespan.

However, the latest update to the story hit people harder than expected.

Just today, Paul Conyngham announced heartbreaking news: his beloved dog Rosie has passed away.

This is not because the AI vaccine was ineffective, but because the production speed of the vaccine could not outpace the pace of death.

Unable to produce the next dose of personalized mRNA cancer vaccine fast enough, Rosie eventually passed away.

But the story does not end here.

Just now, Paul announced the official launch of a startup called Gamgee, which has completed a $4 million seed round of financing led by Founders Fund and participated by YC.

Even though his beloved dog is gone, this "father" is determined to develop clinically validated and scalable canine cancer vaccines for dogs all over the world.

A "Medical Miracle" That Shocked the World

In 2024, 8-year-old Bull Terrier Rosie was diagnosed with "mast cell cancer", and the vet said she only had a few months left to live.

Surgery, chemotherapy, immunotherapy... all treatments failed. Paul, who has 17 years of experience in machine learning, decided: I will save her in my own way!

Spending only $3000 on DNA sequencing of tumor and healthy blood samples, Paul imported massive genomic data into his program. He consulted ChatGPT for biological principles, used AlphaFold to perform 3D modeling of mutant proteins, and finally locked in the exclusive attack target for Rosie's tumor.

3D modeling of Rosie's cancer made by AlphaFold

Part of the code for creating mRNA therapy

With this AI-generated "vaccine formula", he ran around tirelessly and finally persuaded scientists from the University of New South Wales and the University of Queensland to synthesize a vaccine.

In December 2025, after the first injection was administered, a miracle happened.

The huge tumor on Rosie's leg shrank by 50%-75%.

Microscopic analysis showed that a large number of immune cells (macrophages and T cells) were frantically attacking cancer cells. Rosie regained her energy, and she could even jump over the fence and chase rabbits again.

The whole world was ecstatic: the popularization of personalized vaccines is just around the corner!

However, reality is far crueler than movies.

Cancer cells are too cunning: they mutated and developed drug resistance, and Rosie's cancer recurred.

At this point, she urgently needed a second-generation mRNA vaccine customized based on the latest mutations.

However, the speed of traditional laboratories, the cumbersome manual production process, and the lengthy approval mechanism did not allow Rosie to wait for the vaccine.

"I lost my dog because we couldn't make the next mRNA cancer vaccine fast enough," Paul wrote painfully.

As an ordinary person, even with AI knowledge, it is still extremely difficult to quickly customize an mRNA vaccine within one or two months under the existing medical industrial system.

"I shouldn't be the only one who can do this. Having a machine learning background and working day and night for months should not be the threshold for accessing life-saving drugs."

Rosie is gone, but the legacy she left has just begun to take root.

The "Father" Founded Gamgee for His Beloved Dog,

Making Sky-high Vaccines Affordable

To prevent the tragedy from happening again, Paul founded Gamgee, a name derived from *The Lord of the Rings*.

Gamgee's vision is to cure canine cancer and bring personalized mRNA cancer vaccines to dogs all over the world.

At present, they have launched the first prototype of personalized cancer treatment customized for dogs.

Founders Fund, founded by Peter Thiel, did not hesitate to lead the $4 million seed round of financing. A group of top industry figures including the world's top incubator YC, Celine Halioua CEO of Loyal, and Arash Ferdowsi co-founder of Dropbox also joined the investment.

Why do top Silicon Valley VCs pay for a project that "saves dogs"?

Because what Gamgee wants to do is to solve the fatal problem that led to Rosie's death: speed and cost.

It took Paul a whole year to run through the whole process, costing $20,000.

Now, Gamgee is turning this process into a SaaS industrial assembly line.

They have built an "end-to-end" closed-loop platform. Ordinary dog owners no longer need to run around like Paul, and all you need to do is follow these steps.

1. Input tumor samples: Gamgee will send a collection kit to you, and your vet will extract the dog's tumor and healthy tissue samples and send them back.

2. AI deciphers at lightning speed: The samples are directly sent for DNA and RNA sequencing, and Gamgee's software system takes over all subsequent work. The AI algorithm will accurately identify and rank the cancer cell mutation targets worthy of attack from massive data, and retain evidence for every judgment.

3. Output the vaccine: The system automatically outputs the mRNA vaccine design ready for manufacturing. Gamgee coordinates production and cold chain transportation until the vet injects the exclusive vaccine into the dog's body.

Gamgee has set a radical KPI: the goal is to compress the vaccine design time to within 48 hours, and reduce the end-to-end cost of the entire treatment course to $2000!

"Genome sequencing, protein modeling, mRNA synthesis — all the tools are already there. What I built for Rosie is not new science, but a new way of access," Paul said.

This is simply a medical revolution that subverts the entire industry.

Treating 6 Million Cancer-stricken Dogs Worldwide

In terms of commercial prospects, Gamgee demonstrates a strong Silicon Valley-style "data flywheel" mindset.

First of all, why dogs?

This is an extremely large and distressing market with rigid demand.

In the United States alone, about 6 million dogs are diagnosed with cancer every year.

Cancer is the number one killer of adult dogs. The vast majority of dog owners have no choice but to spend thousands of dollars on painful chemotherapy, radiotherapy or surgery.

More importantly, from the perspective of biology and AI algorithm training, dogs are the most perfect subjects for verifying personalized cancer vaccines.

They have a pure gene pool.

Many modern pet dog breeds are cultivated from small populations in the past few hundred years, with a relatively closed gene pool. This genetic concentration makes many breeds (such as Golden Retrievers and Labrador Retrievers) extremely susceptible to specific cancers.

This makes it traceable for AI to find mutation patterns.

In addition, cancer in pet dogs occurs naturally, rather than being artificially induced like in laboratory mice. Their immune systems are intact, and their disease development timeline is very suitable for quickly verifying clinical effects.

The snowball effect of data is Gamgee's most core moat.

At present, datasets of animal genomes and immune responses are still extremely scarce. Every time Gamgee treats a dog, it collects a valuable set of "sequencing + immune response + clinical outcome" data.

Once this data flywheel starts rotating, it will be unstoppable.

Acquire data -> optimize the AI target selection model -> produce the next generation of more effective vaccines -> generate better treatment data -> attract more dogs to receive treatment.

At present, the $4 million seed round of financing has allowed clinical trials to officially start. The first batch of clinical trials is being carried out in Australia, in cooperation with top institutions such as the University of New South Wales and the University of Queensland.

This trial will recruit 30 cancer-stricken dogs, and eligible dogs will participate in the trial and receive personalized vaccines for free.

At the same time, Gamgee is now accepting case registrations globally, and there are already more than 300 dogs on the waiting list.

Ultimate Vision: Starting from Rosie, Treating All Mankind

But Gamgee's ambition goes far beyond canines.

For top investors, what they see is not just the pet medical market, but also the dawn of "N-of-1" medicine, that is, the ultimate personalized medical treatment for individual patients.

Gamgee's ultimate goal is to build a better treatment model based on "N-of-1", crossing species boundaries until it applies to humans.